Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ChemoCentryx, Inc. - Common Stock (NQ:CCXI)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ChemoCentryx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
NASDAQ:CCXI Long Term Shareholder Notice: Investigation over Potential Wrongdoing at ChemoCentryx, Inc. ↗
San Diego, CA -- (SBWIRE) -- 09/15/2021 -- Certain directors of ChemoCentryx, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Topics Lawsuit
News headline image
ChemoCentryx's Return On Capital Employed Overview ↗
Benzinga Pro data, ChemoCentryx (NASDAQ:CCXI) reported Q2 sales of $1.81 million. Earnings fell to a loss of $38.74 million, resulting in a 32.09% decrease from last quarter. In... 
Via Benzinga
News headline image
ChemoCentryx, inc (CCXI) Q2 2021 Earnings Call Transcript ↗
CCXI earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
ChemoCentryx: Q2 Earnings Insights ↗
Shares of ChemoCentryx (NASDAQ:CCXI) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 293.10% year over year to ($0.56... 
Via Benzinga
Analyzing ChemoCentryx's Unusual Options Activity ↗
Shares of ChemoCentryx (NASDAQ:CCXI) saw some unusual opt... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Analyst Ratings For ChemoCentryx ↗
Analysts have provided the following ratings for ChemoCentryx (NASDAQ: 
Via Benzinga
News headline image
Why This ChemoCentryx Analyst Is Bullish ↗
H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ: 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates ↗
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi... 
Via Benzinga
News headline image
10 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
News headline image
Analyzing ChemoCentryx's Unusual Options Activity ↗
ChemoCentryx (NASDAQ:CCXI) shares experienced unusual options activity on Thursday. The stock price moved down to $15.19 following the option alert. Sentiment: BULLISH Option... 
Via Benzinga
News headline image
2 Beaten-Down Biotech Stocks That Could Bounce Back ↗
The market hasn't been kind to these two drugmakers, but both have a chance to turn things around. 
Via The Motley Fool
News headline image
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix ↗
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
News headline image
Is Now the Time to Buy ChemoCentryx Stock? ↗
Analysts following this risky biotech stock have changed their tune. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2021 ↗
Upgrades According to Raymond James, the prior rating for Sunnova Energy International Inc (N... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Wednesday ↗
Keybanc cut Alibaba Group Holding Limited (NYSE: BABA) price target from $275 to $270. Alibaba shares rose 0.5% to $212.60 in pre-market trading. Needham boosted SMART Global... 
Via Benzinga
News headline image
ChemoCentryx Stock Is Approaching A Key Level ↗
ChemoCentryx Inc. (NASDAQ: CCXI) shares traded higher Tuesday after the company announced it filed an amendment to its New Drug Application for avacopan for the treatment of anti-... 
Via Benzinga
News headline image
ChemoCentryx Stock Jumps On Amendment In Avacopan Application, New Goal Date Of October 7 ↗
Following consultations with the FDA, ChemoCentryx Inc (NASDAQ: CCXI) filed an amendment to its marketing application seeking approval for avacopan to treat... 
Via Benzinga
News headline image
Biotech Losers In 2021 That Could Bounce Big In The Second Half ↗
Biotech stocks are tricky investment bets that require careful analysis and scrutiny. Here's a list of biotech stocks that were among the worst performers in the first half but have the potential to... 
Via Talk Markets
News headline image
Biotech Losers In 2021 That Could Bounce Big In The Second Half ↗
Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off... 
Via Benzinga
News headline image
CCXI DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of ChemoCentryx, Inc. of Deadline in Securities Fraud Class Action Lawsuit
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week ↗
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
Via Benzinga
News headline image
CHEMOCENTRYX 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against ChemoCentryx, Inc. - CCXI
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against ChemoCentryx, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Is It Too Late to Buy ChemoCentryx Stock? ↗
This biotech is traveling in uncharted waters. 
Via The Motley Fool
News headline image
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates ↗
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive... 
Via Benzinga
News headline image
CCXI CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against ChemoCentryx, Inc.
NEW YORK, NY / ACCESSWIRE / June 30, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class... 
From Bernstein Liebhard LLP
Via AccessWire
Topics Lawsuit
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ChemoCentryx, Inc. (CCXI)
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
CCXI Approaching Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds ChemoCentryx, Inc. Investors of Class Action and Lead Plaintiff Deadline: July 6, 2021
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
TUESDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.